In the BioHarmony Drug Report Database
Ziprasidone
Geodon (ziprasidone) is a small molecule pharmaceutical. Ziprasidone was first approved as Geodon on 2001-02-05. It is used to treat schizophrenia, schizophrenia spectrum and other psychotic disorders, and tourette syndrome in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 2C, 5-hydroxytryptamine receptor 2A, and D(2) dopamine receptor. In addition, it is known to target sodium-dependent serotonin transporter, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 1B, 5-hydroxytryptamine receptor 7, 5-hydroxytryptamine receptor 1D, histamine H1 receptor, and sodium-dependent noradrenaline transporter.
Trade Name
|
Geodon |
|---|---|
Common Name
|
ziprasidone |
ChEMBL ID
|
CHEMBL708 |
Indication
|
schizophrenia, schizophrenia spectrum and other psychotic disorders, tourette syndrome |
Drug Class
|
Antipsychotic with binding activity on serotonin (5HT2A) and dopamine (D2) receptors |
Image (chem structure or protein)